
-
Uniqure NV NasdaqGS:QURE uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Location: Paasheuvelweg 25, Amsterdam, 1105 BP, Netherlands | Website: https://www.uniqure.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
919.6M
Cash
409M
Avg Qtr Burn
-41.56M
Short % of Float
19.81%
Insider Ownership
8.29%
Institutional Own.
92.11%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details Hemophilia, Rare diseases, Rare genetic disease | Approved Quarterly sales | |
AMT-130 Details Huntington's disease | BLA Submission | |
AMT-260 Details Mesial temporal lobe epilepsy (MTLE) | Phase 1/2 Data readout | |
AMT-162 Details Amyotrophic lateral sclerosis | Phase 1/2 Data readout | |
AMT-191 Details Fabry disease | Phase 1/2 Data readout |